Nuveen
AMLX icon

Nuveen’s Amylyx Pharmaceuticals AMLX Stock Holding History

Nuveen’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.94M Buy
330,521
+65,624
+25% +$1.01M ﹤0.01% 2007
2026
Q1 		$3.68M Sell
264,897
-19,051
-7% -$268K ﹤0.01% 2013
2025
Q4 		$3.43M Buy
283,948
+123,529
+77% +$1.68M ﹤0.01% 2075
2025
Q3 		$2.18M Buy
160,419
+4,883
+3% +$46K ﹤0.01% 2270
2025
Q2 		$997K Buy
+155,536
New +$757K ﹤0.01% 2606
2024
Q2 		– Sell
-137,973
Closed -$392K – 3333
2024
Q1 		$392K Sell
137,973
-883,684
-86% -$11.6M ﹤0.01% 3039
2023
Q4 		$15M Buy
1,021,657
+21,306
+2% +$327K ﹤0.01% 1338
2023
Q3 		$18.3M Buy
1,000,351
+447,277
+81% +$9.46M 0.01% 1093
2023
Q2 		$11.9M Sell
553,074
-58,858
-10% -$1.59M ﹤0.01% 1393
2023
Q1 		$18M Buy
611,932
+15,878
+3% +$552K 0.01% 1113
2022
Q4 		$22M Buy
596,054
+239,367
+67% +$8.49M 0.01% 974
2022
Q3 		$6.38M Buy
356,687
+317,200
+803% +$7.91M ﹤0.01% 1752
2022
Q2 		$761K Buy
39,487
+26,257
+198% +$312K ﹤0.01% 2901
2022
Q1 		$170K Buy
+13,230
New +$299K ﹤0.01% 3215

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Nuveen's AMLX Position: Q2 2026 in Review

Nuveen increased its Amylyx Pharmaceuticals (AMLX) stake by 25% in Q2 2026, buying an estimated $1.01M and bringing the position to 330,521 shares worth $5.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

Nuveen first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. The position peaked at $22M in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Nuveen held 330,521 shares of Amylyx Pharmaceuticals worth $5.94M as of Q2 2026.
  • Nuveen bought 65,624 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2007 holding.
  • Nuveen first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Nuveen's Amylyx Pharmaceuticals position peaked at $22M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.